Articles

Oncology Nurse Navigators Take on COVID-19 Challenge

My first column as Editor-in-Chief was written for the inaugural issue of this publication, which was originally called The Oncology Nurse. Read More ›

COVID-19

More Genetic Testing Needed in Breast Cancer

Oncology nurses and nurse navigators are positioned on the front lines of care, playing an integral role in patients’ battles against cancer. Read More ›

By Mary Bailey

Breast Cancer

Pembrolizumab plus Enzalutamide Shows Activity in Metastatic Castration-Resistant Prostate Cancer

Miami, FL—With too much red tape regarding genetic (ie, hereditary) testing, not enough people are being identified before they have breast cancer, according to Kevin Hughes, MD, FACS, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston. Read More ›

By William King

AUA Highlights

A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting. Read More ›

By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, MN, RN, AOCN

Interview with the Innovators, Video

Videos

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients. Read More ›

Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer

Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation

In a phase 2 study of women with recurrent platinum-sensitive ovarian cancer, safety and efficacy end points favored the combination of niraparib and bevacizumab over niraparib monotherapy. Read More ›

Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer

New study findings represent a significant advance for women with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy. Read More ›

Long-Term Responders to Rucaparib More Likely to Have Deleterious BRCA Mutations

In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events. Read More ›